901 results on '"Naber, Dieter"'
Search Results
2. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study
3. Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.
4. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.
5. Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate
6. What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a “real-world” 2-year follow-up trial
7. Remission in schizophrenia — What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression
8. Disparate effects of first and second generation antipsychotics on cognition in schizophrenia – Findings from the randomized NeSSy trial
9. Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation
10. Kapitel 7 - Pharmakotherapie der Schizophrenie (ICD-10 F2)
11. Organization of Care and Treatment
12. Current Topics
13. Quick Reference
14. Quick reference
15. Organization of care and treatment
16. Current topics
17. Autorinnen und Autoren
18. Pharmakotherapie der Schizophrenie (ICD-10 F2)
19. Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
20. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia
21. Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies
22. Introduction
23. Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM
24. Psychopharmaka und Lebensqualität
25. Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant
26. Autorinnen und Autoren
27. Pharmakotherapie der Schizophrenie (ICD-10 F2)
28. Lebensqualitätsforschung
29. Kapitel 7 - Pharmakotherapie der Schizophrenie (ICD-10 F2)
30. Cross-cultural Quality of Life Research in Mental Health : Conceptual approaches, assessment strategies, empirical results and potential impact
31. Die subjektive Befindlichkeit als Erfolgskriterium antipsychotischer Therapie
32. Subjective well-being in schizophrenia: A randomised controlled open-label 12-month non-inferiority study comparing quetiapine XR with risperidone (RECOVER)
33. Early detection and integrated care for adolescents and young adults with severe psychotic disorders: rationales and design of the Integrated Care in Early Psychosis Study (ACCESS III)
34. Clozapine: the first atypical antipsychotic
35. Validation of a clinician questionnaire to assess reasons for antipsychotic discontinuation and continuation among patients with schizophrenia
36. What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial
37. Differentiating schizoaffective and bipolar I disorder in first-episode psychotic mania
38. One-year functional outcomes of naturalistically treated patients with schizophrenia
39. Response trajectories in “real-world” naturalistically treated schizophrenia patients
40. Brief Psychiatric Rating Scale — Excited Component (BPRS-EC) and neuropsychological dysfunction predict aggression, suicidality, and involuntary treatment in first-episode psychosis
41. Corrigendum to “Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study” [Schizophr. Res. 239 (2022) 83–91]
42. Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia
43. Olanzapine long-acting injection
44. Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia
45. Kapitel 7 - Pharmakotherapie der Schizophrenie (ICD-10 F2)
46. Ventajas y desventajas del tratamiento de combinación con antipsicóticos. Reunión ECNP Consensus, marzo de 2008, Niza
47. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder
48. Constructing an Index for the Subjective Well-Being under Neuroleptics Scale (SWN), Short Form: Applying Structural Equation Modeling for Testing Reliability and Validity of the Index
49. Post-Injection Delirium/Sedation Syndrome in Patients Treated with Olanzapine Pamoate: Mechanism, Incidence, and Management
50. Introduction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.